ML-9

ML-9 was originally identified as a selective Ca2+-calmodulin-dependent myosin light chain kinase inhibitor. Concentrations from 10-100 µM are effective at inhibiting vascular smooth muscle tension and reducing intracellular Ca2+ concentrations. ML-9 also inhibits PKB/Akt activity with an IC50 range of 10-50 µM in rat primary adipocytes. This results in a specific inhibition of insulin-stimulated glucose transport and GLUT4/IGF II receptor translocation to the plasma membrane yet does not interfere with the antilipolytic effect of insulin. Additionally, ML-9 inhibits other serine/threonine kinases including PKA (IC50 = ~20 µM), p90 S6 (IC50 = ~50 µM), and MAP kinase (IC50 = ~35 µM).Formal Name: 1-[(5-chloro-1-naphthalenyl)sulfonyl]hexahydro-1H-1,4-diazepine, monohydrochloride. CAS Number: 105637-50-1. Molecular Formula: C15H17ClN2O2S . HCl. Formula Weight: 361.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, DMSO:PBS (pH 7.2)(1:1): 0.5 mg/ml, Ethanol: 0.5 mg/ml. lambdamax: 229, 300 nm. SMILES: ClC1=CC=CC2=C1C=CC=C2S(=O)(N3CCCN([H])CC3)=O.Cl. InChi Code: InChI=1S/C15H17ClN2O2S.ClH/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18,/h1-2,4-7,17H,3,8-11H2,1H. InChi Key: ZNRYCIVTNLZOGI-UHFFFAOYSA-N.